Phase I dose-escalating study of TAS-106 in combination with carboplatin in patients with solid tumors

Background TAS-106 was designed to inhibit RNA synthesis by blocking RNA polymerases I, II, and III. Methods This was a single-center, open-label, phase I study to identify the maximum tolerated dose (MTD), pharmacokinetics, and biologic effects of the combination of TAS-106 and carboplatin, followi...

Descripción completa

Detalles Bibliográficos
Autores principales: Naing, Aung, Fu, Siqing, Zinner, Ralph G., Wheler, Jennifer J., Hong, David S., Arakawa, Kazuhito, Falchook, Gerald S., Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2013
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913855/
https://www.ncbi.nlm.nih.gov/pubmed/23609829
http://dx.doi.org/10.1007/s10637-013-9964-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913855/
https://www.ncbi.nlm.nih.gov/pubmed/23609829
http://dx.doi.org/10.1007/s10637-013-9964-5

Ejemplares similares